Lawrence F. Eichenfield, MD; Carsten Flohr, PhD; Robert Sidbury, MD; et al.
open access
JAMA Dermatol. 2021;157(10):1165-1173. doi:10.1001/jamadermatol.2021.2830
This randomized clinical trial examines the efficacy and safety of abrocitinib plus topical therapy in adolescents with moderate-to-severe atopic dermatitis.
Marieke E. C. van Winden, MD, MSc; Charlotte R. M. Hetterschijt, MD; Ewald M. Bronkhorst, MSc, PhD; et al.
free access
JAMA Dermatol. 2021;157(10):1174-1181. doi:10.1001/jamadermatol.2021.3020
This cohort study evaluates reasons for watchful waiting and documents the natural course of basal cell carcinoma in patients who chose watchful waiting and reasons to initiate later treatment.
Khalaf Kridin, MD, PhD; Marie-Charlotte Brüggen, MD, PhD; Ser-Ling Chua, PhD; et al.
free access
JAMA Dermatol. 2021;157(10):1182-1190. doi:10.1001/jamadermatol.2021.3154
This cohort study examines culprit drugs and treatment strategies used in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis in European countries.
Katrina Abuabara, MD, MA, MSCE; Morgan Ye, MPH; David J. Margolis, MD, PhD; et al.
free access
JAMA Dermatol. 2021;157(10):1191-1199. doi:10.1001/jamadermatol.2021.2489
This cohort study follows members of 2 British population-based birth cohorts to examine whether early life risk factors and participant characteristics predict patterns of atopic eczema through midlife.
Chloe Kern, BA; Joy Wan, MD, MSCE; Kaja Z. LeWinn, ScD; et al.
free access
JAMA Dermatol. 2021;157(10):1200-1208. doi:10.1001/jamadermatol.2021.2657
This population-based birth cohort study examines the association between atopic dermatitis and symptoms of depression at multiple points across childhood and adolescence and explores the role of potential mediating factors.